Incidence and risk of xerosis with targeted anticancer therapies Journal Article
| Authors: | Valentine, J.; Belum, V. R.; Duran, J.; Ciccolini, K.; Schindler, K.; Wu, S.; Lacouture, M. E. |
| Article Title: | Incidence and risk of xerosis with targeted anticancer therapies |
| Abstract: | BACKGROUND: Many targeted therapies used in the treatment of cancer can lead to the development of xerosis, but the incidence and relative risk of xerosis have not been ascertained. OBJECTIVE: We conducted a systematic review and metaanalysis of clinical trials, to ascertain the incidence and risk of developing xerosis after taking anticancer drugs. METHODS: The PubMed (1966-October 2013), Web of Science (January 1998-October 2013), and American Society of Clinical Oncology abstracts (2004-2013) databases were searched for clinical trials of 58 targeted agents. Results were calculated using random or fixed effects models. RESULTS: The incidences of all- and high-grade xerosis were 17.9% (95% confidence interval [CI]: 15.6-20.4%) and 1.0% (95% CI: 0.9-1.5%), respectively. The risk of developing all-grade xerosis was 2.99 (95% CI: 2.0-4.3), and it varied across different drugs (P < .001). LIMITATIONS: The reporting of xerosis may vary among clinicians and institutions, and the incidence may be affected by age, concomitant medications, comorbidities, and underlying malignancies or skin conditions. CONCLUSION: Patients receiving targeted therapies have a significant risk of developing xerosis. Patients should be counseled and treated early for this symptom to prevent suboptimal dosing and quality of life impairment. Published by Elsevier Inc. |
| Keywords: | antineoplastic agents; antineoplastic agent; prospective study; prospective studies; neoplasms; incidence; neoplasm proteins; enzyme inhibitor; risk; monoclonal antibody; cd20; antibodies, monoclonal; severity of illness index; clinical trials, phase iii as topic; enzyme inhibitors; tumor protein; antineoplastic agents, hormonal; egfr; clinical trials, phase ii as topic; dry skin; skin diseases; meta analysis; mek; antineoplastic hormone agonists and antagonists; mtor; her2; xerosis; bcr-abl; adverse effects; molecularly targeted therapy; phase 2 clinical trial (topic); phase 3 clinical trial (topic); complication; hormone antagonist; molecular targeted therapy; hormone antagonists; raf; hdac; humans; human; vegfr; antagonists and inhibitors; cd52; chemically induced |
| Journal Title: | Journal of the American Academy of Dermatology |
| Volume: | 72 |
| Issue: | 4 |
| ISSN: | 0190-9622 |
| Publisher: | Mosby Elsevier |
| Date Published: | 2015-04-01 |
| Start Page: | 656 |
| End Page: | 667 |
| Language: | English |
| DOI: | 10.1016/j.jaad.2014.12.010 |
| PUBMED: | 25637330 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Export Date: 3 June 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work